Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%
MT Newswires Live
Mar 16
Neurizon Therapeutics (ASX:NUZ) said Michael Thurn has resigned as managing director and chief executive officer, stepping down from his executive responsibilities from March 16, with his contractual notice period concluding in July 2026, according to a Monday Australian bourse filing.
Thurn will continue to serve as a non-executive director until the completion of his notice period, the filing added.
The company said Sergio Duchini will assume the role of interim executive chair until a suitable chief executive is appointed, while a global search for a new CEO is underway with the assistance of executive search firm Coulter Partners.
The company's shares fell 13% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.